Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties

Executive Summary

Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.

You may also be interested in...



Novartis Opts For Alliance Rather Than Acquisition With Alnylam

The announcement that the Swiss giant is collaborating again with Alnylam could spark fresh speculation that the firms are moving closer to a merger – or not.

It's Time For Novartis To Put Its Leqvio Launch Strategy To The Test

Novartis Pharmaceuticals US head Victor Bulto talks to Scrip about the launch of Leqvio; the cholesterol-lowering medicine now approved by the US FDA.

Intellia, Cellex Team Up On New CAR-T Firm, Backed By Blackstone

Blackstone is providing $250m to combine Intellia’s gene editing and Cellex’s cell manufacturing capabilities in a new CAR-T company using Cellex subsidiary GEMoaB’s technology and pipeline as a foundation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142029

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel